DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Arguments
1. Applicant's arguments, with respect to the U.S.C. 101 and 112a rejections, filed 02/16/2026 have been fully considered but they are not persuasive.
Regarding the U.S.C. 101 rejection, the Applicant argues that the claims would not invoke a U.S.C. 101 mental process rejection since they teach a specific tool used to train neural networks. The Examiner respectfully disagrees. When looking at the claims, they do not actively recite the process of training a neural network. Rather the claims only state storing a neural network that has already been trained. If the Applicant were to actively train a neural network, it would be less likely to invoke a U.S.C. 101 - assuming the training does not rely on math, in which case it would be deemed an abstract idea; see MPEP 2016, example 47, claim 2. The Applicant then argues that the claims are not directed to abstract ideas since they integrate the claims into practical application. The Examiner respectfully disagrees. The encoders, decoders, and neural network are all considered additional elements used to perform an abstract idea. While the claims now recite improving classification of the target medical condition, this is not enough to integrate the claims into practical application. If there was an actual treatment step (i.e., the classification of the condition is made and then used to implement some sort of treatment), then that would integrate the concept into practical application. The current amendment would not be enough to integrate the claims into practical application since there is not an actual step about administering treatment or controlling treatments based on the predicted classification. The Examiner points to the MPEP 2106.04(d)(2).
Examiners should keep in mind that in order to qualify as a "treatment" or "prophylaxis" limitation for purposes of this consideration, the claim limitation in question must affirmatively recite an action that effects a particular treatment or prophylaxis for a disease or medical condition. An example of such a limitation is a step of "administering amazonic acid to a patient" or a step of "administering a course of plasmapheresis to a patient." If the limitation does not actually provide a treatment or prophylaxis, e.g., it is merely an intended use of the claimed invention or a field of use limitation, then it cannot integrate a judicial exception under the "treatment or prophylaxis" consideration. For example, a step of "prescribing a topical steroid to a patient with eczema" is not a positive limitation because it does not require that the steroid actually be used by or on the patient, and a recitation that a claimed product is a "pharmaceutical composition" or that a "feed dispenser is operable to dispense a mineral supplement" are not affirmative limitations because they are merely indicating how the claimed invention might be used.
Based on the recited passage, the step of improving the classification of a medical condition is not enough to integrate a judicial exception into practical application. The rejection still stands.
Regarding the U.S.C. 112a rejection, the Applicant argues that the claims would not invoke U.S.C. 112a written description rejection since the specification provides details on how the medical condition is determined from the voice recording. The Examiner respectfully disagrees. The cited portions of the Applicant’s specification only mention using trained neural networks and trained encoders/decoders to take in the data and then classify it as a particular type of medical condition. There are still no actual steps given as to how the trained networks are taking in data and making these classifications, i.e. what is happening between these two steps. The rejection still stands.
Applicant’s arguments, filed 02/16/2026, with respect to the U.S.C. 112b and 102 rejections have been fully considered and are persuasive. The U.S.C. 102 and 112b rejections of the claims have been withdrawn. However, a new U.S.C. 112b rejection has been added in light of the amendments.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
2. Claims 1, 3-5, 7-18, 20, 24-25, 33-36, 52-55, and 71 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. The independent claims 1, 18, 34, and 53 recite a method comprising “a neural network system comprising an encoder, a decoder and one or more classifiers, which are simultaneously trained such that the encoder is configured to generate a biomarker for a target medical condition … the decoder is trained to reconstruct at least a subset of measurements for voice recording digitization from the latent representation… apply[ing] signal processing to a digitization of a voice recording of a subject person to compute a set of measurements for the voice recording…generate[ing]…a biomarker that is discriminative for a target medical condition for a subject person from a voice recording from the subject…and classify[ing], with a first classifier of the one or more classifiers, that uses the biomarker generated by the encoder, the target medical condition, such that the simultaneous training of the encoder, the decoder and the one or more classifiers, including the first classifier, causes the encoder to adjust a quality of the biomarker generated, in a manner that improves classification of the target medical condition”. The limitation, as drafted, is a process that, under its broadest reasonable interpretation, covers performance of the limitation in the mind but for the recitation of generic computer components, encoders/decoders/classifiers/neural networks. For example, a person can listen to the voice or speech of a user and then determine if the user is experiencing a particular medical condition. If a claim limitation, under its broadest reasonable interpretation, covers performance of the limitation in the mind but for the recitation of generic computer components, then it falls within the “Mental Processes” grouping of abstract ideas. The additional limitations of the independent claims are not integrated into a practical application and do not amount to significantly more than well-understood, routine, and conventional elements/limitations.
The additional components of the claims are recited at a high-level of generality such that it amounts no more than any structure that determines medical conditions from speech. For example, the use of encoders/decoders, processors, pre-trained neural networks, and memories in the dependent claims, are merely insignificant extra-solution activity of data gathering because they do not integrate the abstract idea into a practical application. They do not impose any meaningful limits on practicing the abstract idea, thus making the claim directed to an abstract idea.
The additional elements in the dependent claims such as the encoders, decoders, processors, pre-trained neural networks, and memory to classify speech patient data, are merely insignificant extra solution activity because they are recited as structures for data gathering/ They are also well-understood, routine, conventional activity that is widely prevalent or common use in the relevant industry. These are well known in the art as disclosed by the following references: US 20210074036 A1 and WO2021081418A1. Well-understood, routine and conventional activity cannot be significantly more than the abstract idea itself. The claims are not patent eligible.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
3. Claims 1, 3-5, 7-18, 20, 24-25, 33-36, 52-55, and 71 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The claims recite the steps of training classifiers/encoders/decoders to take in the voice of a user, identify biomarkers, and then determine a medical condition using these trained elements. However, the specification does not provide any working examples, guidance, or steps as to how this function is achieved. For example, it is unclear how these encoders/decoders are being trained to determine a medical condition from speech. Rather, the specification only mentions the use of machine learning and algorithm training.
As noted in the MPEP, original claims may lack written description when the claims define the invention in functional language specifying a desired result, but the specification does not sufficiently describe how the function is performed or the result is achieved. For software, this can occur when the algorithm or steps/procedure for performing the computer function are not explained at all or are not explained in sufficient detail (simply restating the function recited in the claim is not necessarily sufficient).
It is not enough that one skilled in the art could write a program to achieve the claimed function because the specification must explain how the inventor intends to achieve the claimed function to satisfy the written description requirement.
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
4. Claims 1, 3-5, 7-18, 20, 24-25, 33-36, 52-55, and 71 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
In regards to claims 1, 18, 34, and 53, it recites “with the encoder that is trained through machine learning”; however, it is unclear if this is the same training discussed above, in relation to the neural network, or if this is a completely different training with different machine learning. Clarification is needed. For examination purposes, the Examiner is interpreting this as the same training.
Claims 3-5, 7-17, 20, 24-25, 33, 35-36, 52, 54-55, and 71 are rejected by virtue of their dependency.
Prior Art Rejections
5. There are currently no art rejections applied to the claims. The contain subject matter that is not found in the art. Such subject matter includes “the biomarker comprises a latent representation produced by the encoder wherein the biomarker is independently usable without retraining the encoder to identify the target medical condition; during simultaneously training of the encoder, decoder, and the one or more classified, the decoder is trained to reconstruct at least a subset of measurements for the voice recording digitization from the latent representation”. The U.S.C. 101 and 112 rejections would need to be addressed.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SKYLAR LINDSEY CHRISTIANSON whose telephone number is (571)272-0533. The examiner can normally be reached Monday-Friday, 7:30-5:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Niketa Patel can be reached at (571) 272-4156. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/S.L.C./Examiner, Art Unit 3792
/NIKETA PATEL/Supervisory Patent Examiner, Art Unit 3792